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Sustained effectiveness of a multifaceted
intervention to reduce potentially
inappropriate prescribing in older patients
in primary care (OPTI-SCRIPT study)
Barbara Clyne1*, Susan M. Smith1, Carmel M. Hughes2, Fiona Boland1, Janine A. Cooper1,2, Tom Fahey1 and on
behalf of the OPTI-SCRIPT study team
Abstract
Background: Potentially inappropriate prescribing (PIP) is common in older people in primary care and can result
in increased morbidity, adverse drug events and hospitalisations. We previously demonstrated the success of a
multifaceted intervention in decreasing PIP in primary care in a cluster randomised controlled trial (RCT).
Objective: We sought to determine whether the improvement in PIP in the short term was sustained at 1-year
follow-up.
Methods: A cluster RCT was conducted with 21 GP practices and 196 patients (aged ≥70) with PIP in Irish primary
care. Intervention participants received a complex multifaceted intervention incorporating academic detailing,
medicine review with web-based pharmaceutical treatment algorithms that provide recommended alternative
treatment options, and tailored patient information leaflets. Control practices delivered usual care and received
simple, patient-level PIP feedback. Primary outcomes were the proportion of patients with PIP and the mean
number of potentially inappropriate prescriptions at 1-year follow-up. Intention-to-treat analysis using random
effects regression was used.
Results: All 21 GP practices and 186 (95 %) patients were followed up. We found that at 1-year follow-up, the
significant reduction in the odds of PIP exposure achieved during the intervention was sustained after its
discontinuation (adjusted OR 0.28, 95 % CI 0.11 to 0.76, P = 0.01). Intervention participants had significantly lower
odds of having a potentially inappropriate proton pump inhibitor compared to controls (adjusted OR 0.40, 95 % CI
0.17 to 0.94, P = 0.04).
Conclusion: The significant reduction in the odds of PIP achieved during the intervention was sustained after its
discontinuation. These results indicate that improvements in prescribing quality can be maintained over time.
Trial registration: Current controlled trials ISRCTN41694007.
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Introduction
Medication use in older people can improve well-
being and quality of life; however, drug-related prob-
lems such as medication errors and adverse drug
events (ADEs) are common [1]. Evidence suggests
that prescribing in this population can be potentially
inappropriate [2]. Medications are termed potentially
inappropriate where their risks outweigh the benefits
and when a safer therapeutic alternative is available
[3]. Potentially inappropriate prescribing (PIP) is es-
timated to affect between 10 and 50 % of community
dwelling older people internationally, increasing the
risk of morbidity, ADEs, hospitalisations and health
expenditure in this population [2, 4–8].
Interventions such as computerised decision sup-
port systems (CDSS), pharmacist interventions and
multifaceted interventions may be useful strategies in
reducing PIP in different health care settings [9–12].
We have previously demonstrated that a multifaceted
intervention was effective in decreasing PIP in older
patients in primary care using a short-term follow-
up, on intervention completion at 4–6 months [13].
The short-term results indicated that patients in the
intervention group had significantly lower odds of
having PIP than patients in the control group (ad-
justed odds ratio (OR) 0.32, 95 % confidence interval
(CI) 0.15 to 0.70, P = 0.02). The mean number of PIP
drugs in intervention was 0.70, compared to 1.18 in
control (P = 0.02). The intervention was effective in
reducing proton pump inhibitor prescribing (adjusted
OR 0.30, 95 % CI 0.14 to 0.68, P = 0.04), but not
other drug classes [13].
The use of such short-term follow-up is a common
criticism, raising concerns about the long-term sus-
tainability of such interventions [2]. Even when in-
appropriate medications are ceased, evidence
indicates that they might be restarted, particularly
where multiple prescribers are involved [14]. Post-
trial follow-up is therefore recommended to assess if
short-term changes persist. Post-trial follow-up is ne-
cessary to assess if trial effects diminish, remain con-
stant or increase after the randomised interventions
are formally discontinued. The objective of this study
was to determine whether the immediate improve-
ment in PIP in the short-term was sustained at 1 year
follow-up.
Methods
A cluster randomised controlled trial (RCT) was
conducted in Irish primary care to alter general
practitioner (GP) PIP-related prescribing. The study
protocol, intervention development and short-term
outcomes (intervention completion at 4–6 months)
have been reported in detail previously and are sum-
marised in brief below [13, 15, 16]. The Research
Ethics Committee of the Irish College of General
Practitioners (ICGP) approved the study.
Recruitment and randomisation
A total of 65 general practices from the greater Dublin
area were invited to participate in this study with 21
(32 %) consenting. Consenting practices were assisted
by the study team in identifying and recruiting approxi-
mately 10 patients per practice. Patients were eligible
where they were aged ≥70 years and had pre-existing
PIP (as determined by having one or more pre-specified
PIP indicators, see Appendix [16]). In total, 196 patients
were recruited. Fifty-three per cent of the pre-specified
indicators were present in this population. Practices were
allocated using minimisation to intervention or control
after baseline data collection. It was not possible to blind
patients or GPs to allocations; however, the outcome asses-
sor was blinded.
Intervention and control groups
The intervention group (11 practices, 99 patients) re-
ceived a multifaceted intervention involving academic
detailing with a pharmacist on how to conduct GP-
led medicines review with participating patients.
Medicine reviews were supported by web-based
pharmaceutical treatment algorithms for GPs provid-
ing evidence-based alternative treatment options to
PIP drugs and tailored patient information leaflets
[15]. The control group (10 practices, 97 patients) de-
livered usual care and received one-off simple patient-
level PIP feedback (see Table 1).
Formal support for the intervention finished at
6 months (intervention completion), and all practices
(intervention and control) received a report summar-
ising participating patients and their PIP profile for
use for internal audit purposes. GPs and patients
returned to their usual practice, with no attempt to
encourage further medicine review or alteration to
medications.
Outcomes and statistical analysis
Outcome data were collected at 1-year post-
intervention completion (i.e. 1 year after formal sup-
port for the intervention stopped). Patient records
were used to collect outcome data, i.e. medication
and health service use data for all eligible partici-
pants. Data was extracted by review of the patient’s
chart (either electronic or paper based depending on
the practice system).
Clyne et al. Implementation Science  (2016) 11:79 Page 2 of 8
The primary outcomes were the proportion of pa-
tients with PIP and the mean number of PIP drugs.
The proportion of patients with PIP is presented and
was analysed using a random effects logistic regres-
sion with the individual as the unit of analysis and
the practice included as the random effect to control
for the effects of clustering. Baseline covariates (age,
gender, baseline number of PIP drugs, baseline num-
ber of repeat medications) and minimisation factors
(number of GPs, practice location) were included in
the model. The mean number of PIP drugs was cal-
culated per group, and a mean difference calculated
using a cluster level t test. Intention-to-treat analysis
using random effects regression was used.
Secondary outcomes assessed differences between
intervention and control in relation to individual
drugs (using random effects logistic regressions) and
health service utilisation including the number of GP
visits and in-patient days (using random effects mul-
tiple regressions).
Results
Figure 1 displays the flow of participants through
the RCT. All GP practices and 186 (95 %) patients
were followed up at 1 year. At baseline, receipt of
proton pump inhibitors at maximum therapeutic
dosage for more than 8 weeks was the most fre-
quently occurring PIP, with 60 % of participants hav-
ing this indicator [13].
Primary outcomes
At 1-year follow-up, the proportion of patients with
PIP drugs was 0.51 in the intervention group com-
pared to 0.76 in the control group. Intervention group
participants had significantly lower odds of having PIP
than control participants (adjusted OR 0.28, 95 % CI 0.11
to 0.76, P = 0.01) (Table 2). The mean number of PIP
drugs in the intervention group was 0.61 (SD 0.7) com-
pared to 1.03 (SD 0.8) in the control group (P = 0.01).
Intervention participants had significantly lower odds of
having a potentially inappropriate proton pump inhibitor
compared to controls (adjusted OR 0.40, 95 % CI 0.17 to
0.94, s = 0.04). No statistically significant differences were
found for other drug-specific outcomes.
New PIP
Between baseline and 1-year follow-up, a total of 34
new instances of PIP were identified in 30 patients
(13 % of total sample). In the intervention group, 12
(13 %) participants had a total of 16 new instances of
PIP, compared to 18 (20 %) participants with 18 new
Table 1 Summary of OPTI-SCRIPT intervention and control
groups
Intervention The intervention consisted of:
(1) Academic detailing with a
pharmacist
One session (30 min) where
a pharmacist visited the practice
to discuss PIP, medicine review and
the web-based pharmaceutical
treatment algorithms
(2) Medicine review with
web-based
pharmaceutical treatment
algorithms.
GPs were asked to conduct
one eview per patient using
the web-based platform to
guide them through the
process. The GP was
presented with the specific
PIP drug(s) for each patient,
and for each PIP drug, there
was a treatment algorithm
with the following structure:
a. The individual PIP with reason
for concern
b. Alternative pharmacological
and non-pharmacological
treatment options
c. Background information
(where relevant)
(3) Patient information leaflets to
give to patients during the review.
Each leaflet:
a. Described the PIP and the
reasons as to why it may be
inappropriate
b. Outlined the alternative
pharmacological and
non-pharmacological
therapies GPs may offer
Control Control practices delivered
usual care. Usual care for
public general medical
services (GMS) patients allows
GPs to give a prescription on
a monthly or three monthly
basis.
Control practices received
simple patient-level PIP postal
feedback in the form of a list
summarising the medication
class to which the individual
patient’s potentially inappropriate
medication belonged.
Control practices did not receive
an academic detailing
visit or were not prompted to
carry out medicines review
with the individual patients.
GMS general medical services, PIP potentially inappropriate prescribing
Source: Clyne et al. [13]
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instances of PIP in the control group (P = 0.38). The
majority (81.2 %) had only 1 new PIP. The majority
of new prescriptions identified as potentially inappro-
priate were proton pump inhibitors (44.1 %).
Health service utilisation
In terms of health service utilisation, there were no
statistically significant differences between interven-
tion and control groups. Patients in the control
group had an average of 11.7 GP visits compared to
12.2 in the intervention group over the 12-month
period. Just over 20 % of intervention and control
groups had an in-patient stay.
Discussion
Using 1-year follow-up, we demonstrated that the sig-
nificant decreases in PIP rates achieved during our
intervention were sustained once it was discontinued.
Fig. 1 Flow of practices and patients through study
Table 2 Proportion of patients with PIP at 1-year follow-up
Characteristic Intervention N (%) Control N (%) Adjusteda odds ratio (95 % CI) P value
PIP at baseline 99 (100) 97 (100)
PIP at 1-year follow-up 51 (51) 74 (76)
No PIP 1-year follow-up 48 (49) 23 (24) 0.28 (0.11 to 0.76) 0.01
aAdjusted for baseline number of PIP, age, gender, number of GPs in practice, practice location
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Our findings substantiate previous findings that have
demonstrated that interventions lasting for a limited
time period (e.g. educational and multifaceted inter-
ventions) can have a long-lasting carry-over effect on
improving PIP [17, 18].
An array of factors may have contributed to the
sustained effect observed in this study. Firstly, this
cohort of older patients experienced few hospitalisa-
tions over the 1-year follow-up period, reducing the
potential for medication changes or potential errors
to arise at these transitions of care (i.e. moving be-
tween primary and secondary care) [19]. Hence, pre-
scribing may have been more likely to stay stable
over time. Secondly, the effect may also have been
maintained due to the medications in question, par-
ticularly prescribing of proton pump inhibitors,
which may be easier to maintain than other medica-
tions. Finally, the intervention itself may be an influ-
ential factor. Patients were identified as having PIP
which would have been noted in the patient health
care record; therefore, at future consultations, GPs
may be more cognisant of not restarting the identi-
fied PIP. A combination of these factors may have
contributed to the persistence of the effect from this
one-off intervention.
The OPTI-SCRIPT intervention primarily affected
potentially inappropriate proton pump inhibitor pre-
scribing, which was highly prevalent at baseline
(60 %). We found no impact on other included med-
ications (e.g. benzodiazepines), likely because of the
small numbers of patients exposed to these PIP
drugs in this study. The prescription of inappropriate
proton pump inhibitor is a substantial driver for the
prevalence of PIP both in Ireland [20] and inter-
nationally [21–24]. The use of proton pump inhibi-
tors has increased substantially during the past
decade internationally, potentially due to increased
long-term use for ulcer prophylaxis and perceived
lack of serious adverse side effects [24]. However, a
significant proportion of this prescribing has been
found to be inappropriate, and consequently, there
has been an increased focus on reducing inappropri-
ate use to improve patient outcomes and decrease
costs [24, 25].
A small proportion of the intervention group (13 %) had
new PIP at 1-year follow-up, though this was lower than
those in the control group (20 %), suggesting some effect
on GP prescribing in the intervention practices. The new
instances of PIP in intervention practices mainly related to
sustained maximal dosage of proton pump inhibitors. From
the data presented here, it is unclear if the proton
pump inhibitor was indeed appropriate or if it was
initiated by the GP or another physician. Proton
pump inhibitors initiated in hospitals are frequently
continued in primary care, even when inappropriate
[26].
Improvements may be observed in control group
participants due to reactive effects of being studied
(i.e. the possible Hawthorne effect). The control
group in this study did alter their prescribing pat-
terns slightly. This may be explained by the fact that
during the intervention, they received simple feed-
back about their patients based on baseline data col-
lection and a report on patient PIP at intervention
completion. Feedback has been found to promote
slight improvements in professional practice but is most
effective when it is provided intensively [27]. In anticipa-
tion of this improvements in the control group occurring,
we analysed anonymised data from the Primary Care
Reimbursement Service (PCRS) pharmacy claim database
of dispensed medications (a national prescribing database
of GP and pharmacy claims), as a national contemporan-
eous comparison group. Analysis of this group highlighted
that the crude odds of having PIP were lower in the
OPTI-SCRIPT intervention group compared to the na-
tional comparator group [13].
The study has a number of strengths, including being
conducted in ‘real-world’ practices, the low rate of attrition
of from the study (primarily due to the nature of the out-
come data) and the completeness of the prescription data.
However, there are some limitations including the geo-
graphic restriction to a region in Ireland, limiting external
validity. In all, 32 % of invited GP practices were recruited
which is lower than that reported in other primary
care studies [28]. The intervention was effective at
decreasing the most prevalent PIP in this study, pro-
ton pump inhibitors at maximum therapeutic dosage
for more than 8 weeks. Potentially inappropriate
proton pump inhibitor is a problem in Ireland and
internationally, indicating that this intervention
could be generalizable to other settings. However, it
has been argued that future studies of PIP should
focus on the management of genuinely high-risk
medicines (i.e. prescribing likely to lead to adverse
clinical outcomes [29]), rather than global lists of
potentially inappropriate medications [30, 31]. It is
therefore important to establish the effectiveness of
the OPTI-SCRIPT intervention in altering prescrib-
ing, other than proton pump inhibitor prescribing.
Conclusions
Changes in PIP occur against a background of
escalating polypharmacy and changes in prescribing
patterns of specific medications over time [20]; how-
ever, these findings indicate that improvements in
prescribing quality can be maintained over time.
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Appendix
Table 3 Selected prescribing criteria/prescribing indicator [16]
Criteria Concern Estimated
prevalence in
Irelanda
PPI for peptic ulcer disease at full therapeutic dosage for >8 weeks Earlier discontinuation or dose reduction for maintenance/
prophylactic treatment of peptic ulcer disease, oesophagitis or
GORD indicated
4.1–16.7 %
NSAID (>3 months) for relief of mild joint pain in osteoarthritis Simple analgesics preferable and usually as effective for pain
relief
1.1–8.8 %
Long term (i.e. >1 month), long-acting benzodiazepines, e.g. chlordi-
azepoxide, flurazepam, nitrazepam, chlorazepate and benzodiaze-
pines with long-acting metabolites, e.g. diazepam
Risk of prolonged sedation, confusion, impaired balance, falls 3.0–9.1 %
Any regular duplicate drug class prescription, e.g. 2 concurrent
opiates, NSAIDs, SSRIs, loop diuretics, and ACE inhibitors. Excludes
duplicate prescribing of drugs that may be required on a PRN basis,
e.g. inhaled beta 2 agonists (long and short acting) for asthma or
COPD, and opiates for management of breakthrough pain
Optimisation of monotherapy within a single drug class
should be observed prior to considering a new class of drug
2.2–6.0 %
TCAs with an opiate or calcium channel blocker Risk of severe constipation 0.4–2.0 %
Aspirin at dose >150 mg/day Increased bleeding risk, no evidence for increased efficacy 0.1–1.0 %
Theophylline as monotherapy for COPD/asthma Risk of adverse effects due to narrow therapeutic index 0.6–1.2 %
Use of aspirin and warfarin in combination without histamine H2
receptor antagonist (except cimetidine because of interaction with
warfarin) or PPI
High risk of GI bleeding 0.3–1.1 %
Doses of short-acting benzodiazepines, doses greater than loraze-
pam (Ativan®), 3 mg; oxazepam (Serax®), 60 mg; alprazolam (Xanax®),
2 mg; temazepam (Restoril®), 15 mg; and triazolam (Halcion®),
0.25 mg
Total daily doses should rarely exceed the suggested
maximums
1.0–1.5 %
Prolonged use (>1 week) of first generation antihistamines, i.e.
diphenydramine, chlorpheniramine, cyclizine, promethazine
Risk of sedation and anticholinergic side effects <1.0 %
Warfarin and NSAID together Risk of GI bleeding 0.7–1.7 %
Calcium channel blockers with chronic constipation May exacerbate constipation <1.0 %
NSAID with history of peptic ulcer disease or GI bleeding, unless
with concurrent histamine H2 receptor antagonist, PPI or
misoprostol
Risk of peptic ulcer relapse <1.0 %
Bladder antimuscarinic drugs with dementia Risk of increased confusion, agitation <1.0 %
TCAs with constipation May worsen constipation <1.0 %
Digoxin at a long-term dose >125 μg/day (with impaired renal
function)
Increased risk of toxicity <1.0 %
<1.0 %
Thiazide diuretic with a history of gout May exacerbate gout <1.0 %
Glibenclamide (with type 2 diabetes mellitus) Risk of prolonged hypoglycaemia <1.0 %
Aspirin with a past history of peptic ulcer disease without histamine
H2 receptor antagonist or PPI
Risk of bleeding <1.0 %
Prochlorperazine (Stemetil®) or metoclopramide with parkinsonism Risk of exacerbating parkinsonism <1.0 %
TCAs with dementia Risk of worsening cognitive impairment <1.0 %
TCAs with glaucoma Likely to exacerbate glaucoma <1.0 %
TCAs with cardiac conductive abnormalities Pro-arrhythmic effects <1.0 %
Long-term corticosteroids (>3 months) as monotherapy for
rheumatoid arthritis or osteoarthritis
Risk of major systemic corticosteroid side effects <1.0 %
Bladder antimuscarinic drugs with chronic prostatism Risk of urinary retention <1.0 %
NSAID with heart failure Risk of exacerbation of heart failure <1.0 %
TCAs with prostatism or prior history of urinary retention Risk of urinary retention <1.0 %
Systemic corticosteroids instead of inhaled corticosteroids for
maintenance therapy in COPD/asthma
Unnecessary exposure to long-term side effects systemic
steroids
<1.0 %
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